Dacomitinib is from which country?

Dacomitinib (Dacomitinib) was approved for medical use in the United States in September 2018, in Japan in 2019, and in the European Union in 2019 for the treatment of epidermal growth factor Non-small cell lung cancer with mutated EGFR gene, is a selective and irreversible inhibitor of EGFR, developed by Pfizer Laboratories Div Pfizer Inc (Pfizer Pharmaceutical Co., Ltd.) research and development and production.

Dacomitinib is designed as (2E)-N-16-4-(piperidine-1-yl)butan-2-enamide, an oral highly selective quinazoline moiety of a second-generation tyrosine kinase inhibitor characterized by irreversible binding to the ATP domain of the epidermal growth factor receptor family kinase domain. Some evidence in the literature suggests the therapeutic potential of dacomitinib in epithelial ovarian cancer models 1 , although further studies are needed. Dacomitinib demonstrated linear kinetics after single-dose and multiple dose-ranging studies.

The original drug of dacomitinib has been launched in China and has entered the scope of Class B medical insurance. The price of the common specification 15mg*30 tablets per box may be more than 1,000 yuan; the European version of dacomitiniboriginal drug sold overseas, the specification 45mg*30 tablets may be more than 20,000 yuan per box (the price may fluctuate due to exchange rates). Currently, there are cheaper generic drugs of dacomitinib sold overseas. Their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 45mg*30 tablets produced by a Lao pharmaceutical factory may be around a few hundred yuan per box (the price may fluctuate due to exchange rate effects).